Constitutional Challenges to the Medicare Drug Price Negotiation Program

In this episode, the Fifth Circuit Court of Appeals affirms a lower court's decision to uphold the drug pricing provisions of the Inflation Reduction Act of 2022. A group of pharmaceutical organizations challenged the law, arguing it unconstitutionally delegated legislative power and violated Eighth Amendment protections against excessive fines. The court determined that Congress provided enough guidance to satisfy the nondelegation doctrine and that the law's excise tax did not constitute a criminal penalty. Additionally, the judges rejected Fifth Amendment due process claims, ruling that private companies and healthcare providers have no inherent right to specific Medicare reimbursement levels. Ultimately, the court concluded that participation in federal healthcare programs remains voluntary, meaning the government may set the financial terms for its own purchases.